Combined detection of SDC2/ADHFE1/PPP2R5C methylation in stool DNA for colorectal cancer screening

Background Colorectal cancer (CRC) is a disease of global concern, and its increasing incidence suggests the need for early and accurate diagnosis. The aim of this study was to investigate the value of combined detection of SDC2, ADHFE1 and PPP2R5C gene methylation in stool samples for early CRC scr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2023-09, Vol.149 (12), p.10241-10253
Main Authors: Li, Ben, Liu, Shanglong, Gao, Yuan, Zheng, Longbo, Lu, Yun
Format: Article
Language:English
Subjects:
Adenoma
Cancer Research
Cancer screening
Clinical trials
Colorectal cancer
Colorectal carcinoma
CTR
CTR2100046662
DNA methylation
Feces
Hematology
Internal Medicine
Medical screening
Medicine
Medicine & Public Health
Oncology
Polyps
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Colorectal cancer (CRC) is a disease of global concern, and its increasing incidence suggests the need for early and accurate diagnosis. The aim of this study was to investigate the value of combined detection of SDC2, ADHFE1 and PPP2R5C gene methylation in stool samples for early CRC screening. Methods Stool samples from patients with CRC ( n  = 105), advanced adenoma (AA) ( n  = 54), non-advanced adenoma (NA) ( n  = 57), hyperplastic or other polyps (HOP) ( n  = 47) or no evidence of disease (NED) ( n  = 100) were collected from September 2021 to September 2022. The methylation levels of SDC2, ADHFE1 and PPP2R5C were quantified by quantitative methylation-specific polymerase chain reaction (qMSP), and faecal immunochemical testing (FIT) was performed. The diagnostic value was assessed using reporter operating characteristic (ROC) curve analysis. Results The sensitivity of combined detection of SDC2/ADHFE1/PPP2R5C methylation in predicting CRC (0–IV) was 84.8%, the specificity was 98.0%, and the AUC was 0.930 (95% CI 0.889–0.970). Compared to FIT and serum tumour biomarkers, it showed better diagnostic performance for different stages of CRC. Conclusion The results of this study verified that the methylation levels of SDC2, ADHFE1 and PPP2R5C in stool DNA were significantly increased in CRC patients. Combined detection of SDC2/ADHFE1/PPP2R5C methylation is a potential non-invasive diagnostic method for CRC and precancerous lesion screening. Clinical trial registration Chinese Clinical Trials Registry, ChiCTR2100046662, registered on 26 May 2021, prospective registration.
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-023-04943-4